Objective: To estimate the prevalence of post-vaccination seropositivity against SARS-CoV-2 and identify its predictors in Peruvian Social Health Insurance (EsSalud) personnel in 2021.
Methods: We conducted a cross-sectional study in a representative simple stratified sample of EsSalud workers. We evaluated IgG anti-SARS-CoV-2 antibodies response (seropositivity) by passive (previous infection) and active immunization (vaccination), and epidemiological and occupational variables obtained by direct interview and a data collection form. Descriptive and inferential statistics were used with correction of sample weights adjusted for non-response rate, and crude and adjusted odds ratio (OR) and geometric mean ratio (GMR) with their respective 95% confidence intervals (95%CI) were estimated.
Results: We enrolled 1077 subjects. Seropositivity was 67.4% (95%CI: 63.4-71.1). Predictors of seropositivity were age (negative relation; p < 0.001), previous infection (aOR = 11.7; 95%CI: 7.81-17.5), working in COVID-19 area (aOR = 1.47; 95%CI: 1.02-2.11) and time since the second dose. In relation to antibody levels measured by geometric means, there was an association between male sex (aGMR = 0.77; 95%CI: 0.74-0.80), age (negative relation; p < 0.001), previous infection (aGMR = 13.1; 95%CI:4.99-34.40), non-face-to-face/licensed work modality (aGMR = 0.78; 95%CI: 0.73-0.84), being a nursing technician (aGMR = 1.30; 95%CI: 1.20-1.41), working in administrative areas (aGMR = 1.17; 95%CI: 1.10-1.25), diagnostic support (aGMR = 1.07; 95%CI: 1.01-1.15), critical care (aGMR = 0.85; 95%CI: 0.79-0.93), and in a COVID-19 area (aGMR = 1.30; 95%CI: 1.24-1.36) and time since receiving the second dose (negative relation; p < 0.001).
Conclusions: Seropositivity and antibody levels decrease as the time since receiving the second dose increases. Older age and no history of previous infection were associated with lower seropositivity and antibody values. These findings may be useful for sentinel antibody surveillance and the design of booster dose strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710108 | PMC |
| http://dx.doi.org/10.1016/j.tmaid.2022.102514 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Varicella Vaccination Strategy: A Study on Age and Dose Impacts on Antibody Levels.
Vaccines (Basel)
December 2024
Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China.
Seropositivity study of Varicella in Healthy Populations in Guangzhou, China. Infection with varicella-zoster virus (VZV) leads to skin and mucous membranes blisters and the complications can be life threatening. A seroepidemiological study conducted from 2020 to 2022 in Guangzhou, China, aimed to evaluate varicella antibody levels.
View Article and Find Full Text PDFLong-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults.
J Travel Med
January 2025
UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Herston, Australia.
Background: Japanese encephalitis virus (JEV) is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond five years remain limited.
Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia.
The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV).
Hum Vaccin Immunother
December 2025
Division of Virology, Department of Pathology, University of Cambridge, England, UK.
Cytomegalovirus (CMV) is a leading cause of congenital infections and significant health complications in immunocompromised individuals. With no licensed CMV vaccine available, the development of the mRNA-1647 offers promising advancements in CMV prevention. We have reviewed results from Phase 1 and 2 clinical trials of the mRNA-1647 vaccine, demonstrating robust immune responses in both seronegative and seropositive participants.
View Article and Find Full Text PDFQuantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
Vaccine
January 2025
Center of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Article Synopsis
- Epidemiological studies show that factors like pre-vaccination immune status, age, gender, and vaccination history affect how people respond to influenza vaccines, but results vary across different studies.* -
- A new Bayesian model was created to analyze the relationships between these host factors and antibody responses after vaccination, revealing that pre-vaccination antibody levels and vaccination history significantly affect post-vaccine antibody dynamics.* -
- The findings suggest that individuals who have been vaccinated less frequently and have lower pre-vaccination antibody levels experience longer durations of effective protection (seroprotection) from the vaccine, with notable differences observed in antibody response to different influenza subtypes.*
Assessing Post-Vaccination Seroprevalence and Enhancing Strategies for Lumpy Skin Disease Vaccination in Korean Cattle.
Animals (Basel)
November 2024
College of Veterinary Medicine & Bio-Safety Research Institute, Jeonbuk National University, Iksan 54596, Republic of Korea.
Lumpy skin disease (LSD), caused by the LSD virus (LSDV), a dsDNA virus of the genus Capripoxvirus, represents a significant cross-border infectious threat, particularly impacting cattle and water buffaloes through transmission by blood-feeding insects. Traditionally endemic to Southern Africa, LSD has rapidly spread over the past decade through the Middle East to Eastern Europe and China, reaching Korea in October 2023. This outbreak prompted a nationwide vaccination campaign, addressing both the disease's severe economic impact and its status as a notifiable disease under the World Organisation for Animal Health.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!